ScholarWorks@SUNGKYUNKWAN UNIVERSITY

Browsing by Kim, TY[Kim, T-Y]Author

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 6 of 6

SCIESCOPUS
Does participation in clinical trials influence on survival in patients with metastatic breast cancer?

Kim, TY[Kim, T-Y]; Kim, SB[Kim, S-B]; Yoon, JH[Yoon, J. H.]; Lee, KH[Lee, K. H.]; Koh, SJ[Koh, S-J]; Lee, SE[Lee, S. E.]; Chae, Y[Chae, Y.]; Lee, KS[Lee, K. S.]; Lee, KE[Lee, K. E.]; Won, HS[Won, H. S.], et al.

ArticleIssue Date2016CitationCANCER RESEARCH, v.76PublisherAMER ASSOC CANCER RESEARCH
SCIESCOPUS
Exploratory biomarker analysis from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer(MBC): Korean cancer study group trial (KCSG BR13-11)

Kim, JY[Kim, J-Y]; Lee, EJ[Lee, E. J.]; Park, KH[Park, K. H.]; Im, SA[Im, S-A]; Kim, SB[Kim, S-B]; Sohn, SH[Sohn, S. H.]; Lee, KS[Lee, K. S.]; Chae, YS[Chae, Y. S.]; Lee, KH[Lee, K. H.]; Kim, JH[Kim, J. H.], et al.

ArticleIssue Date2019CitationCANCER RESEARCH, v.79, no.4PublisherAMER ASSOC CANCER RESEARCH
SCIESCOPUS
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park, K[Park, K.]; Vansteenkiste, J[Vansteenkiste, J.]; Lee, KH[Lee, K. H.]; Pentheroudakis, G[Pentheroudakis, G.]; Zhou, C[Zhou, C.]; Prabhash, K[Prabhash, K.]; Seto, T[Seto, T.]; Voon, PJ[Voon, P. J.]; Tan, DSW[Tan, D. S. W.]; Yang, JCH[Yang, J. C. H.], et al.

ArticleIssue Date2020CitationANNALS OF ONCOLOGY, v.31, no.2, pp.191 - 201PublisherOXFORD UNIV PRESS
SCIESCOPUS
Role of endocrine therapy in premenopausal patients with hormone receptor-positive metastatic breast cancer, compared with postmenopausal patients: Diachronic analyses from nationwide cohort in Korea (KCSG BR 14-07)

Kim, TY[Kim, T-Y]; Ahn, JH[Ahn, J-H]; Yoon, JH[Yoon, J. H.]; Sohn, JH[Sohn, J. H.]; Kim, GM[Kim, G. M.]; Lee, KH[Lee, K. H.]; Park, YH[Park, Y. H.]; Koh, SJ[Koh, S-J]; Lee, SE[Lee, S. E.]; Chae, Y[Chae, Y.], et al.

ArticleIssue Date2016CitationCANCER RESEARCH, v.76PublisherAMER ASSOC CANCER RESEARCH
SCIESCOPUS
The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Park, IH[Park, I. H.]; Im, SA[Im, S-A]; Jung, KH[Jung, K. H.]; Sohn, JH[Sohn, J. H.]; Park, YH[Park, Y. H.]; Park, KH[Park, K-H]; Nam, BH[Nam, B-H]; Kim, JH[Kim, J. H.]; Kim, HJ[Kim, H-J]; Lee, S[Lee, S.], et al.

ArticleIssue Date2017CitationCANCER RESEARCH, v.77PublisherAMER ASSOC CANCER RESEARCH
SCIESCOPUS
The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Park, IH[Park, I. H.]; Lee, KS[Lee, K. S.]; Im, SA[Im, S-A]; Jung, KH[Jung, K. H.]; Park, KH[Park, K. H.]; Im, YH[Im, Y-H]; Lee, S[Lee, S.]; Kim, YJ[Kim, Y. J.]; Kim, HJ[Kim, H-J]; Lee, S[Lee, S.], et al.

ArticleIssue Date2013CitationCANCER RESEARCH, v.73PublisherAMER ASSOC CANCER RESEARCH
1
STATISTICS
Total View :5,749,289
Today View :2,817

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어